Takeda’s Weekly Oral Proteasome Inhibitor Ixazomib Passes First Pivotal Test
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Company plans to submit data from positive TOURMALINE-MM1 study of Velcade follow-on ixazomib in relapsed myeloma to regulators; drug set for 2015 filing.